Leukemia, B-cell, Lymphoma, B-Cell
Conditions
Keywords
CAR-T, CD19, CD22
Brief summary
This is a single arm study to evaluate the efficacy and safety of CD19 and CD22 targeted CAR-T cells therapy for patients with relapsed/refractory B Cell Leukemia and Lymphoma.
Detailed description
Although the CD19 targeted CAR-T cell therapies have gained significant results in patients with relapsed and refractory B-cell Leukemia and Lymphoma. There are patients who resisted anti-CD19 CAR-T cells or with CD19 negative relapse. To make further improvement, We launch such a clinical trial using CD19 and CD22 targeted CAR-T cells for patients with relapsed and refractory B Cell Leukemia and Lymphoma to evaluate the efficacy and safety of CD19 and CD22 targeted CAR-T cell therapy.
Interventions
BIOLOGICALCD19 and CD22 targeted CAR-T cells
A single infusion of CD19 and CD22 CAR-T cells will be administered intravenously
Sponsors
Chongqing Precision Biotech Co., Ltd
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
3 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Signed written informed consent; 2. Diagnose as relapsed /refractory B Cell Leukemia and Lymphoma, and meet one of the following conditions: 1. Failed to standard chemotherapy regimens; 2. Relapse after complete remission, high-risk and / or refractory patients ; 3. Relapse after hematopoietic stem cell transplantation; 3. For patients with Ph + ALL, the following conditions must be met: those who have received a standard induction chemotherapy regimen and who have not achieved complete remission after TKI treatment or have relapsed after remission (cannot tolerate TKI treatment or have contraindications to TKI treatment or the presence of TKI class) Except for drug resistant patients)； 4. Evidence for cell membrane CD19 and CD22 expression; 5. All genders, ages: 3 to 75 years； 6. The expect time of survive is above 12 weeks; 7. KPS\>60； 8. No serious mental disorders ; 9. Left ventricular ejection fraction ≥50% 10. Sufficient hepatic function defined by ALT/AST≤3 x ULN and bilirubin≤2 x ULN; 11. Sufficient renal function defined by creatinine clearance≤2 x ULN; 12. Sufficient pulmonary function defined by indoor oxygen saturation≥92%; 13. With single or venous blood collection standards, and no other cell collection contraindications; 14. Ability and willingness to adhere to the study visit schedule and all protocol requirements.
Exclusion criteria
1. Have received CAR-T therapy or other genetically modified cell therapy before screening； 2. Participated in other clinical research within 1 month before screening； 3. Have received the following anti-tumor treatment before screening: Have received chemotherapy, targeted therapy or other experimental drug treatment within 4 weeks, except those who have confirmed disease progression after treatment; 4. Live attenuated vaccine within 4 weeks before screening; 5. Convulsion or stoke within past 6 months; 6. Previous history of other malignancy; 7. Presence of uncontrolled active infection; 8. Subjects with positive HBsAg or HBcAb positive and peripheral blood HBV DNA titer is higher than the lower limit of detection of the research institution; HCV antibody positive and peripheral blood HCV RNA titer is higher than the lower limit of detection of the research institution; HIV antibody positive; syphilis primary screening antibody positive; 9. Pregnant or breasting-feeding women; 10. Any situation that investigators regard not suitable for attending in this study or may affect the data analysis.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adverse events that related to treatment | 2 years | Therapy-related adverse events will be recorded and assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0). |
| The response rate of CD19 and CD22 CAR-T treatment in patients with relapse/refractory B Cell Leukemia and Lymphoma | 6 months | The response rate of CD19 and CD22 CAR-T treatment will be recorded and assessed according to the National Comprehensive Cancer Network Guideline. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cellular kinetics of CD19 and CD22 positive cells in Bone marrow | 1 years | In vivo (bone marrow) rate and quantity of CD19 and CD22 positive cells were determined by means of flow cytometry |
| Levels of IL-6 in Serum | 3 months | In vivo (Serum) quantity of IL-6 |
| Levels of IL-10 in Serum | 3 months | In vivo (Serum) quantity of IL-10 |
| Levels of TNF-α in Serum | 3 months | In vivo (Serum) quantity of TNF-α |
| Rate of CD19 and CD22 CAR-T cells in bone marrow and peripheral blood | 2 years | In vivo (bone marrow and peripheral blood) rate of CD19 and CD22 CAR-T cells were determined by means of flow cytometry |
| Duration of Response (DOR) of CD19 and CD22 CAR-T treatment in patients with refractory/relapsed B Cell Leukemia and Lymphoma | 2 years | DOR will be assessed from the first assessment of CR/CRi to the first assessment of recurrence or progression of the disease or death from any cause (censored) |
| Progress-free survival(PFS) of CD19 and CD22 CAR-T treatment in patients with refractory/relapsed B Cell Leukemia and Lymphoma | 2 years | PFS will be assessed from the first CAR-T cell infusion to death from any cause or the first assessment of progression (censored). |
| Overall survival(OS) of CD19 and CD22 CAR-T treatment in patients with refractory/relapsed B Cell Leukemia and Lymphoma | 2 years | OS will be assessed from the first CAR-T cell infusion to death from any cause (censored) |
| Levels of CRP in Serum | 3 months | In vivo (Serum) quantity of CRP |
| Quantity of CD19 and CD22 CAR copies in bone marrow and peripheral blood | 2 years | In vivo (bone marrow and peripheral blood) quantity of CD19 and CD22 CAR copies were determined by means of qPCR |
Countries
China
Contacts
Primary ContactZhi Yang, PhD
Backup ContactYingzi Zhang
Outcome results
None listed